Foley Hoag LLP represented The Valens Company Inc. (“Valens”), a leading manufacturer of cannabis products, in gaining approval for an application to list its common shares on the Nasdaq Capital Market ("Nasdaq"). Valens’ common shares commenced trading on Nasdaq under the symbol "VLNS" on December 9, 2021. Valens' common shares continue to be listed and trade on the Toronto Stock Exchange (TSX) under the symbol "VLNS."
The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The company provides proprietary cannabis processing services, in addition to best-in-class product development, manufacturing, and commercialization of cannabis consumer packaged goods. The Valens Company's high-quality products are formulated for the medical, health and wellness, and recreational consumer segments, and are offered across all cannabis product categories with a focus on quality and innovation. The company also manufactures, distributes, and sells a wide range of CBD products in the United States through its subsidiary Green Roads, and distributes medicinal cannabis products to Australia through its subsidiary Valens Australia. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets.
Foley Hoag attorneys Ryan Rourke Reed
, Stacie Aarestad
, Jesse Alderman
, Michael McQueeny
, Talia Coyne, Cecilia Oyediran
, and Rayanna Smith
represented Valens in the transaction.